Latest News

07-04-2014 Shareholder Update
03-03-2014 Investor presentation
28-02-2014 Half Yearly Report and Accounts
07-02-2014 Response to ASX price query
31-01-2014 Appendix 4C - quarterly
News archive

Subscribe to our newsletter

Receive our latest news and announcements instantly


Phylogica is a leading peptide drug discovery company that utilises proprietary Phylomer peptide libraries and screening methodologies to identify unique peptide drug candidates for its pharmaceutical and biotechnology partners.

Phylomer® libraries contain the world's largest and most structurally diverse array of natural peptides. These peptides, known as Phylome® peptides, are sourced from evolutionary diverse microbes and they represent a new class of biological therapeutics. Phylomer® peptides display exceptional structural stability, specificity and affinity thereby giving them the potential to address disease targets that are intractable to small molecules and other protein biologics including antibodies. Read more



© 2014 Phylogica    |    ABN 48 098 391 961    |    Privacy Statement
Last updated: 18-08-2014    |    Website by Harmonic New Media and College Hill Life Sciences